Drug Profile
NBI 69733
Latest Information Update: 28 Feb 2011
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Neurocrine Biosciences
- Class Erectile dysfunction therapies
- Mechanism of Action Dopamine D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Erectile dysfunction; Female sexual dysfunction
Most Recent Events
- 07 Jul 2006 No development reported - Phase-II for Erectile dysfunction in USA (unspecified route)
- 07 Jul 2006 No development reported - Phase-II for Female sexual dysfunction in USA (unspecified route)
- 20 Jan 2005 Phase-II clinical trials in Erectile dysfunction in USA (unspecified route)